Treating Urothelial Bladder Cancer
This book aims to bring together the current research and discussions surrounding bladder cancer management. New technologies and therapeutic agents have become increasingly effective at treating urothelial bladder cancer and have created a range of oppor
- PDF / 4,016,220 Bytes
- 128 Pages / 504.63 x 737.01 pts Page_size
- 21 Downloads / 249 Views
123
Treating Urothelial Bladder Cancer
Francesco Soria • Paolo Gontero Editors
Treating Urothelial Bladder Cancer
Editors Francesco Soria University of Turin Torino Italy
Paolo Gontero University of Turin Torino Italy
ISBN 978-3-319-78558-5 ISBN 978-3-319-78559-2 (eBook) https://doi.org/10.1007/978-3-319-78559-2 Library of Congress Control Number: 2018950479 © Springer International Publishing AG, part of Springer Nature 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by Springer Nature, under the registered company Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Bladder cancer represents the most common genitourinary cancer in male population after prostate cancer and the most common in women, with around 80,000 estimated new cases during 2016 only in the United States. It is mainly a disease of the elderly, with the majority of new diagnoses occurring in the decade between 75 and 84 years. Therefore, with the aging of population, bladder cancer will become even more frequent and develop in an even bigger public health challenge in the near future. This will lead to a mandatory multidisciplinary management, which will call in not only the urologist, medical oncologist, and radiotherapist but also the general practitioner, geriatrician, and public health manager. Moreover, after many years, novel technologies and new therapeutic agents are becoming a reality in the treatment of urothelial bladder cancer, carrying the opportunity to change the natural history of the disease. This will lead, as already happens for other cancers, to more and more individualized treatments. Therefore, one of the major challenge will be the correct selection of the right treatment for the right patient. All the figures which are taking part in the mana
Data Loading...
